Caris Life Sciences, Inc. (CAI)
| Market Cap | 8.98B +5.5% |
| Revenue (ttm) | 989.61M +85.4% |
| Net Income | 105.14M |
| EPS | 0.37 |
| Shares Out | 282.60M |
| PE Ratio | 85.61 |
| Forward PE | 114.70 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,554,204 |
| Open | 29.50 |
| Previous Close | 30.26 |
| Day's Range | 28.80 - 32.15 |
| 52-Week Range | 14.19 - 33.65 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 31.62 (-0.44%) |
| Earnings Date | Nov 4, 2026 |
About CAI
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecula... [Read more]
Financial Performance
In 2025, Caris Life Sciences's revenue was $812.03 million, an increase of 96.97% compared to the previous year's $412.26 million. Losses were -$537.96 million, 42.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for CAI stock is "Buy." The 12-month stock price target is $31.62, which is a decrease of -0.44% from the latest price.
News
Caris Life Sciences price target raised to $35 from $25 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on Caris Life Sciences (CAI) to $35 from $25 and keeps an Overweight rating on the shares. The firm updated models…
Caris Life Sciences price target raised to $36 from $30 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Caris Life Sciences (CAI) to $36 from $30 and keeps a Buy rating on the shares. The firm adjusted…
Caris Life Sciences price target raised to $35 from $23 at BofA
BofA raised the firm’s price target on Caris Life Sciences (CAI) to $35 from $23 and keeps a Buy rating on the shares as part of a specialty diagnostics group…
Caris Life Sciences initiated with a Neutral at UBS
UBS initiated coverage of Caris Life Sciences (CAI) with a Neutral rating and $28 price target The firm initiated and resumed 25 life science and diagnostics tools companies. UBS views…
Caris Life Sciences to present new research at IASCL 2026
Caris Life Sciences (CAI) announced that researchers from Caris and the Caris Precision Oncology Alliance will present seven studies at the International Association for the Study of Lung Cancer, IASL...
Caris Life Sciences price target raised to $33 from $32 at BTIG
BTIG raised the firm’s price target on Caris Life Sciences (CAI) to $33 from $32 and keeps a Buy rating on the shares.
Caris Life Sciences price target raised to $26 from $25 at Evercore ISI
Evercore ISI raised the firm’s price target on Caris Life Sciences (CAI) to $26 from $25 and keeps an Outperform rating on the shares.
Caris Life Sciences reports Q2 EPS 0c, consensus 1c
Reports Q2 revenue $263.7M, consensus $238.08M. “This was a record quarter, with approximately 59,200 clinical cases, up more than 12% sequentially, reflecting sustained demand and the payoff from inv...
Caris Life Sciences sees 2026 revenue $1.03B-$1.04B, consensus $”This was a reco
16:28 EDT Caris Life Sciences (CAI) sees 2026 revenue $1.03B-$1.04B, consensus $”This was a reco
Caris Life Sciences Earnings Call Transcript: Q2 2026
Record Q2 with 59,200 cases and 45% revenue growth, driven by commercial expansion and new product launches. Raised full-year guidance to $1.03–$1.04 billion, with continued investment in capacity and sales force. Strong demand for Caris Detect and robust financial position support ongoing innovation.
Caris Life Sciences Earnings release: Q2 2026
Caris Life Sciences released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Caris Life Sciences Slides: Q2 2026
Caris Life Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Caris Life Sciences Quarterly report: Q2 2026
Caris Life Sciences has published its Q2 2026 quarterly earnings report on August 5, 2026.
Caris Life Sciences price target lowered to $30 from $31 at TD Cowen
TD Cowen lowered the firm’s price target on Caris Life Sciences (CAI) to $30 from $31 and keeps a Buy rating on the shares. The firm adjusted targets in the…
Caris Life Sciences expands prostate cancer offering with PTEN IHC testing
Caris Life Sciences (CAI) will offer in-house PTEN immunohistochemistry, or IHC, testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is...
Caris Life Sciences price target lowered to $23 from $28 at BofA
BofA lowered the firm’s price target on Caris Life Sciences (CAI) to $23 from $28 and keeps a Buy rating on the shares as part of the firm’s Q2 earnings…
Caris Life Sciences price target lowered to $25 from $30 at Evercore ISI
Evercore ISI lowered the firm’s price target on Caris Life Sciences (CAI) to $25 from $30 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech,…
Caris Life Sciences announces commercial launch of Caris Detect test
Caris Life Sciences (CAI) announced the commercial launch of Caris Detect, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages...
Caris Life Sciences announces dual listing on NYSE Texas
Caris Life Sciences (CAI) announced the dual listing of its common stock on NYSE Texas effective on June 17, further expanding its presence in the public markets. Caris’ shares will…
Caris Life Sciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Precision oncology is advancing rapidly, with strong technology leadership in whole exome and transcriptome sequencing, a growing product pipeline, and robust AI-driven data assets. Financial performance is strong, with continued reinvestment and a share repurchase reflecting confidence in future growth.
Caris Life Sciences announces $100M share repurchase program
Caris Life Sciences (CAI) announced that its Board of Directors has authorized a share repurchase program for up to $100M of the company’s outstanding common stock.
Caris Life Sciences Transcript: AGM 2026
The meeting covered board elections and auditor ratification, with all proposals approved. No shareholder questions were submitted, and final voting results will be published in a Form 8-K filing.
Caris Life Sciences assumed with a Peer Perform at Wolfe Research
Wolfe Research assumed coverage of Caris Life Sciences (CAI) with a Peer Perform rating and no price target The firm is positive on the company’s tissue therapy selection dominance but…
Caris Life Sciences assumed at Peer Perform from Outperform at Wolfe Research
Wolfe Research analyst Mike Polark downgraded Caris Life Sciences (CAI) to Peer Perform from Outperform with no price target as the analyst assumed coverage of the stock. Published first on…